George et al9." have isolated and partially characterized membranous MP in supernatant preparations of banked plasma, serum, and platelet concentrates. They found a population of MP bearing platelet membrane glycoprotein (GP) IIb that increased over storage time in the supernatant plasma of platelet concentrates (PC) at a rate dependent on the type of agitation used." Solberg et all2 observed membranous MP in PC by scanning electron microscopy and Coulter Counter studies, especially in samples from concentrates that showed an increase in pH over the storage period. We13 and Solberg et all4 have shown that platelet membrane fragments in the cell-free supernate express a major fraction of the overall procoagulant platelet factor 3 activity (PF3) in PC. Although the presence of membranous MP in stored PC has been well demonstrated, direct enumeration and population analysis has not been possible until the application of flow cytometry.
was obtained by adding a known amount of fluorescent beads to each sample before analysis of a set number of counts on the flow cytometer. The addition of platelet activation inhibitors (prostaglandin E-1, theophylline, and aprotinin) to the anticoagulant during preparation of PC combined with a reduction in surface area of the storage container caused approximately a 40% reduction in the number of MP appearing during storage relative to donormatched controls. In addition, the inhibited concentrates had ESICULATION 
OF PLATELETS has been observed
V under a variety of conditions. More than two decades ago, Wolf' found a "coagulant material in minute particulate form . . . originating from platelets" in platelet-poor plasma and serum. Budding of vesicles from the platelet plasma membrane has been observed in electron micrographs of activated platelet^,^-^ and was proposed to be the origin of platelet membrane material in the supernatant plasma. Sandberg et aI6 reported the release of small procoagulant vesicles from platelets stimulated with collagen. More recently, Sims et a1' demonstrated that sublytic treatment of platelets with the membrane attack complex of complement directly caused activation and vesiculation of platelets, resulting in the formation of microparticles (MP) that supported prothrombinase assembly as analyzed by flow cytometry. ' George et al9." have isolated and partially characterized membranous MP in supernatant preparations of banked plasma, serum, and platelet concentrates. They found a population of MP bearing platelet membrane glycoprotein (GP) IIb that increased over storage time in the supernatant plasma of platelet concentrates (PC) at a rate dependent on the type of agitation used." Solberg et all2 observed membranous MP in PC by scanning electron microscopy and Coulter Counter studies, especially in samples from concentrates that showed an increase in pH over the storage period. We13 and Solberg et all4 have shown that platelet membrane fragments in the cell-free supernate express a major fraction of the overall procoagulant platelet factor 3 activity (PF3) in PC. Although the presence of membranous MP in stored PC has been well demonstrated, direct enumeration and population analysis has not been possible until the application of flow cytometry.
In this report, we used the flow cytometer to identify light-scattering material smaller than platelets in supernatant plasma from PC and investigated its surface antigen profile as well as estimated the concentration of MP based on a "competitive counting assay" described herein. MP were discriminated from "background" light scatter by their uptake of the fluorescent hydrophobic dye 3,3'-Dihexyloxacarbocyanine iodide (DiOC,) . With these techniques, we evaluated the effect of addition of a combination of platelet activation inhibitors (prostaglandin E-1 [PGE-84% less platelet factor 3 (PF3) activity in the supernatant and 61% less released lactic dehydrogenase. A reduction in surface area of the container in the controls partially offset these differences. A significant correlation was found (r, = .748) between PF3 levels and the concentration of larger MP. The inhibitors did not reduce the small number of MP found in stored platelet-poor plasma. Surface antigen analysis showed that the majority of MP in PC were plateletderived; most were positive for glycoprotein (GP) llbllla (73%) and/or for GPlb (43% to 46%). We conclude that procoagulant MP are released from platelets during storage as a result of platelet activation augmented by interaction of platelets with the bag wall. 0 1991 by The American Society of Hematology.
11, theophylline, and aprotinin) on the generation of MP during storage of PC at 22°C over a 10-day storage period. It was previously demonstrated that these inhibitors and a reduced surface-to-volume ratio (S/V) of the storage container improve the preservation of platelet-cell integrity over extended storage period^.'^ Now we present evidence that these optimized conditions retarded MP generation and inhibited release of PF3 and lactic dehydrogenase (LDH) into the supernatant plasma during the storage period.
antibody, HLE (1.0 pdmL), was purchased from Coulter Immunology. Also, a murine IgG MoAb, D2-10 (1.0 pLg/mL), specific for human glycophorin was obtained from AMAC, Inc (Westbrook, ME) to detect erythrocyte-derived MP. Nonimmune goat IgG (2 pg/mL) purchased from Sigma was used as a blocking reagent.
The secondary antibodies used were R-phycoerythrin (PE)-labeled goat antimouse IgG (heavy chain specific) (10 pLg/mL) and PE-labeled goat antirabbit Ig (polyvalent) (50 pLg/mL), both purchased from Fisher Biotech (Orangeburg, NY).
To construct a paired experimental design to test the effect of inhibitors, two half-units of whole blood (250 mL) were collected in a single sitting from normal donors as previously des~ribed.'~ The first half-unit was collected into 35 mL of CPDA-1 (Fenwal half-unit collection sets, No. 4R6004, Deerfield, IL) through a 17-gauge catheter. Immediately following attachment of a second collection set to the catheter, the other half-unit was collected into 35 mL of CPDA-1 supplemented with PGE-1 (delivered in 35 pL of absolute ethanol), theophylline, and aprotinin. The final concentrations of inhibitors in the whole blood were: 300 nmol/L, 1.9 mmol/L, and 348 KIUlmL, respectively. PC were prepared by established centrifugation t e c h n i q~e '~ and transferred to PL-732 storage bags, which were clamped to give an SN of 7 cm2/mL or 4 cm*/mL for the control unit (as indicated), and 4 cm*/mL for the unit supplemented with inhibitors for reasons discussed elsewhere.I6 All PC were stored at 22°C on a slow (2 Hz), tumbler agitator (Helmer Labs, Fenwal). Platelet-poor plasma (PPP) removed during concentrate preparation was also stored at 22T, but on a flat-bed, to-and-fro agitator.
On day 1 of the experiment, pairs of inhibited and control PC were prepared from each of two donors. On days 3 and 6, this process was repeated with two more donors on each day to produce a total of six pairs of concentrates. On day 7 all 12 PC were sampled and analyzed as described below; at this point the concentrates had been stored 1, 4, or 6 days. In the first experiment the concentrates were sampled again on day 10 and analyzed; at this point the concentrates had been stored 4, 7, or 9 days. There was no significant difference in initial platelet counts (Coulter Counter S Plus IV) between the inhibited concentrates and the matched controls (paired t-test, 1.28 rf: 0.19 X 109/mL v 1.18 rf: 0.26 x 109/mL; P = .18). The entire experiment was conducted again at a later date with six more donors to confirm the original findings and then once more with the controls stored at SN = 4 cm*/mL to assess this separate effect, as well as variations in sample preparation technique.
Samples of PC or PPP were centrifuged at 22°C in an Eppendorf model 5415 microfuge at 15,000g for 30 seconds or 2 minutes to remove sedimentable cells. This step was found to be necessary for the determination of MP count with the addition of fluorescent beads as described below. One aliquot (1.0 mL) of each supernatant plasma was filtered through a 0.2-pm Acrodisc (Gelman Sciences, Ann Arbor, MI) to remove as many MP as possible, then diluted 1:lO in Hematall to permit assessment of background light scatter. An unfiltered aliquot was similarly diluted 1:10 in Hematall, and 1.0 mL of the filtered and unfiltered sample was spiked with 20 pL 0.5-pm fluorescent beads (diluted 15000 in Hematall) for MP counting. A third aliquot of supernatant plasma was diluted 1:10 in Hematall and treated with 2.0 pLof 100-pM DiOC, at 37°C for 30 minutes to identify membranous material. DiOC, is a hydrophobic cyanine dye whose fluorescence has been used to measure membrane potential in cells and membranous vesicles." Other aliquots of 1:lO diluted supernatant plasma were incubated with equal volumes (100 pL) of a primary antibody (from those described above) for 30 minutes at 22"C, followed by 100 pL of appropriate secondary antibody with blocking reagent (see above) for 30 minutes at 22°C without Preparation of PC.
Experimental design.
MPsamplepreparation.
washing. The percentage of antigen-positive MP was estimated by placing a cursor at the upper edge of the control antibody fluorescence distribution so as to include 95% of the counts as negative for specific antibody binding. This approach potentially underestimates the degree of antibody binding if the fluorescence of small, positive particles overlaps with large negatives.
All samples were analyzed on a Becton Dickinson FACS 440 flow cytometer (San Jose, CA) with Consort 40 data management system. Triggering was set on linear side scatter with laser power at 600 mW. The filtered aliquot treated with fluorescent beads was run first to set thresholds on light scatter signals to exclude background turbidity and electronic noise. The settings were considered acceptable if on a plot of fluorescence versus forward angle light scatter, 85% or more of the counts in the filtered sample appeared to be beads. The specific fluorescence of beads could be easily distinguished from autofluorescence of MP. Next, the DiOC,-treated sample was run to confirm that MP observed in the native suspension (unfiltered supernatant plasma) were membranous. If greater than 20% of the counts appeared to be negative for DiOC,, the thresholds were readjusted. Then, the unfiltered sample containing beads was analyzed without further changes in settings to determine MP concentration by the formula given below. Finally, the samples treated with antibodies were run to determine surface antigen distribution.
Estimates of MP concentration were calculated from the relationship of MP fractional counts to the known concentration of fluorescent beads through the following formula:
The bead concentration produced from addition of 20 pLof 15000 stock to 1.0 mL Hematall (as with the plasma samples described above) was determined by accumulating total counts to dryness (with back flushing) on 10 250-pL mock samples. By this method, the bead concentration was found to be 9.30 rf: 0.38 X 1OS/mL. By way of confirmation, the concentration of the stock bead suspension was calculated from the following equation supplied by the bead manufacturer: 6W X 10" Number of beads/mL = p x a x 4 3 where: W = grams of bead polymer per mL in latex, 4 = diameter in microns of latex particles; and p = density of the bead polymer in grams per mL.
This calculation for the OS-pm fluorescent beads gave a stock concentration of 3.42 x lO"/mL. Because the bead dilution in each counting sample was 1:255,000, the calculated bead concentration should be 1.34 x 106/mL. The estimate on the flow cytometer was 69% of this value, which we considered to be in good agreement.
For the experiments described herein, only one preparation of fluorescent beads was used so as to reduce variability.
Assays of LDH as a marker of platelet lysis or loss of membrane integrity were performed on supernatant plasma samples with a Technicon RA-1000 (Tarrytown, NY) and compared with total levels in freeze-thawed whole PC to calculate the percent of LDH released during storage. PF3 activity in supernatant plasma samples prepared as above was measured by a chromogenic assay as described elsewhere.'-'
Other tests and assays. Figure 1B shows the staining pattern of MP treated with the hydrophobic dye DiOC,. When the light scatter gain was increased, or the threshold decreased from the settings displayed, the amount of DiOC,-negative counts increased dramatically as a band of noise in the lower left corner of the display. We restricted our analysis to MP that showed uptake of DiOC, on the assumption that this material was membrane-bound and the DiOC,-negative material was not. The intensity of fluorescence of DiOC, is dependent on polarization across the membrane, and thus it is useful as a label for intact membrane-bound particles. Filtration of the supernatant plasma through a 0.2-pm pore filter before analysis reduced the MP count by 96% f 6% (n = 16), supporting our notion that the events being counted at these settings were not electronic noise or plasma lipoproteins. Attempts to identify and quantify membranous MP in native platelet suspensions by flow cytometry were complicated by several factors: (1) the number of platelets (and beads, when added) overwhelmed the counting of MP except when impractically high total counts were accumulated; (2) the use of DiOC, to resolve membranous MP from background light scatter events was compromised by pronounced uptake in the intact platelets; and (3) the forward angle light scatter detector on the available flow cytometer was inoperative in the log mode, which prevented adequate display of the distribution of intact platelets versus smaller particles. Therefore, platelets were sedimented from each concentrate sample by a short, high-speed centrifugation step before analysis for MP determination or PF3 assay. In one experiment, two different protocols were used: 30 seconds or 2 minutes at 15,000g (7,500g-minute or 30,000g-minute). The clearance of platelets was 96.8% and 99.1%, respectively (n = 12). Mean cell volumes of remaining platelets on the Coulter histogram were less than half that of the platelet concentrate suspension, suggesting that in both supernatant prep- arations the unsedimented particles were smaller than or at the lower limit of the usual distribution of intact platelets (data not shown). The term "microparticles" was applied to all of the nonsedimenting material, although the fraction larger than 0.5-pm beads may have included platelet-sized particles. The MP concentration was on average 2.5-fold higher in samples centrifuged 30 seconds versus 2 minutes (P = .004), and the PF3 activity levels were 2.0-fold higher (P = .01) as illustrated in the tables that follow. Unless otherwise noted, the data presented below were obtained in samples prepared by a 2-minute centrifugation.
RESULTS

Quantitation of MP in PC.
Inhibition of MP generation during storage. In the first analysis of paired PC prepared with or without activation inhibitors, the units were at 1, 4, or 6 days of storage. The control concentrates were stored at S/V = 7 cm2/mL, which represents typical conditions of a 60-mL vol in a 300-mL bag. Total MP counts (quadrant I11 + IV) in samples centrifuged for 30,000g-minute were 41% lower (P = .025) in the inhibited concentrates relative to the matched controls (Fig 2A) . The second analysis performed 3 days later, with the concentrates at 4, 7, or 9 days of storage, showed 42% less MP (P = .003) with the inhibitors versus controls (Fig 2B) . The observed difference was entirely due to a lower count in the larger MP (quadrant IV), as shown in Fig 3; there was no significant difference in smaller MP (quadrant 111, P = .7) between inhibited and control concentrates. With both analyses included, there was a significant increase in total MP over storage time for the inhibited and control PC, with the MP count in the controls increasing at twice the rate of the inhibited (3.4 v 1.7 x 106/mL/d, This same study was repeated in another set of six donors with only a single analysis when the concentrates were at days 1, 4, and 6 of storage. No significant (P = .622) difference in day 1 platelet counts was noted between the control and inhibited PC. Again we found that the inhibitors had no effect on MP counts in quadrant I11 (P = .l), but the counts in quadrant IV were 40% lower in the inhibited concentrates (P = .03).
When the experimental design was altered so that the control concentrates were stored at S/V = 4 cm*/mL, as were the inhibitor-treated concentrates, the difference in MP counts and PF3 levels between inhibited and control units was reduced but still significant (Table 1) . These P = .01).
For ------samples were analyzed after either a 7,500g-minute or 30,000g-minute centrifugation step to determine the effect of MP-separation technique on the comparison of results. The effect of the inhibitors was apparent in both preparations, although slightly less pronounced in the 7,500g-minute samples. The PPP bags stored along with the concentrates in the first experiment had a much lower concentration of MP than the PC at all time points, but there was no demonstrable effect of inhibitors on MP count in the PPP (Fig 4) . The average concentration of MP in the PPP bags with inhibitors (30,000g-minute supernatant samples; 5.4 5 2.3 x lo6 MP/mL) was not significantly different (P = .7) from the average concentration in the paired controls (5.1 * 2.5 x lo6 MP/mL). The concentration of total MP in the PPP did not significantly increase from the first analysis to the second analysis in either the control bags (P = .8) or the inhibited bags ( P = 3). In the repeated studies, we noted again a significantly lower concentration of MP in the PPP bags as compared with the PC ( P < .001). Also, there was no significant (P = .3) difference in total MP concentration between the control and inhibited PPP bags, consistent with the first set of findings discussed above.
Assays of released PF3 were performed on the same supernatant plasma samples as those prepared for MP estimation to test the correlation between procoagulant activity and MP count. The data showed consistently lower supernatant PF3 in the PC containing inhibitors versus the paired control concentrates stored at S/V = 7 cmZ/mL (Fig 5) , amounting to an average difference of 84% f. 9% between pairs (P < .001). In the study with controls stored at S/V = 4 cmz/mL, the inhibited concentrates had 53% less PF3 activity in the 30,000g-minute supernate (Table 1) . There was no effect of the inhibitors on the PF3 assay, as assessed with dilutions of frozen-thawed platelets in buffer with or without PGE-1 + theophylline + aprotinin (data not shown). Over all time points in all concentrate samples prepared by centrifugation at 30,000g-minute, there was a significant correlation by Spearman ranking between PF3
Correlation of MP count with other parameters. "P = .01 "P = .02 "P = ,007 ' P = .02
Pairs of donor-matched PC at day 1 (n = 2). day 4 (n = 2), or day 6 (n = 2) were analyzed together after a 2-minute or 30-second centrifugation at MP counts in units of 106/mL (f 1 SD).
PF3 activity in units defined by frozen-thawed platelets = 1 U/mL supernatant PF3. LDH released expressed as a percent of total platelet content. Differences in means shown in parentheses as a percentage of the controls. Abbreviation: ND, not determined.
15,OOOg.
levels and MP count (rs = ,697, P < .Ol), specifically in the larger MP distribution (quadrant IV; r, = .748, P < .01) rather than the smaller (quadrant 111; r, = .04, P > .lo). In the samples centrifuged 7,500g-minute, the correlation between PF3 activity and MP count decreased to r, = .486 (P > .lo). There was very little measurable PF3 in the stored PPP bags, and we did not find a significant difference in PF3 levels in the inhibitor-containing PPP versus controls
In the repeat of this study with the control concentrates stored at S/V = 7 cm2/mL, we demonstrated a similar reduction of 89% in PF3 levels in the inhibitor-treated concentrates (P = .001). Again no difference in PF3 levels was found in the PPP bags between inhibited and controls Extracellular LDH assays indicated that less LDH release had occurred in the inhibitor-treated concentrates (P = 3.
(P = 4. versus the paired controls over all time points (Fig 6) . There was an average difference of 61% 2 11% between pairs (P < .001) in the experiment with control concentrates at S/V = 7 cm2/mL, and an average difference of 46% +-6% when the controls were stored at S/V = 4 cm*/mL (P = .02). A significant correlation was found between released LDH levels and total MP count ( I = S22, P < .Ol), suggesting that platelet vesiculation may involve a transient or slow leakage of cytoplasmic contents.
Both single and dual label ("tw0-c0l0r") experiments were performed to examine the presence of platelet-specific or other cellular antigens on the supernatant MP. DiOC, was added after the final antibody incubation to examine the distribution of antigen and DiOC, positivity simultaneously. With each of these antibodies, the negative and positive populations appeared to be distinct and well-separated on the single parameter fluorescence histograms. Less than 5% of the MP in any sample tested were positive with the pan-leukocyte (HLE) or erythrocyte (anti-glycophorin) antibodies. The 10E5 antibody to platelet GPIIbIIIa stained an average of 73% 2 13% (n = 24) of the DiOC,-positive MP in samples from inhibited or control PC. There was no demonstrable change in the distribution of 10E5 positivity of MP over storage time. A polyclonal antiserum raised in rabbits against whole human platelets appeared to stain an average of 62% * 18% (n = 18) of DiOC,-positive MP. The AN-51 and SZ-2 antibodies to platelet GPIb stained an average of 46% 2 24% (n = 18) and 43% * 20% (n = 18) of the MP, respectively. Less than 5% of the MP that stained with any of these antibodies were negative for DiOC,. Example fluorescence patterns are shown in Fig 7. The small amount of very bright PE-positive material apparent with each of the antibodies, including the non-immune control, was later found to be aggregates of the PE-labeled second antibody.
In the comparison of different experimental designs, there appeared to be a nonsignificant increase (1.2-fold to Surface antigens on h4P.
1.4-fold) in antibody positivity (AN-51,10E5, SZ-2, and the polyclonal) in the control samples when centrifuged 7,500g-minute versus 30,000g-minute. A larger increase (1.7-fold to 2.5-fold) was noted with the shorter centrifugation in samples from inhibitor-treated concentrates that was statistically significant (P < .01). Interpretation of this finding is not straightforward. For either supernate preparation, there was no significant difference (P 2 .2) in marker positivity between samples from control concentrates and those treated with inhibitors. Thus, it seemed that the inhibitors decreased the number of platelet-derived MP found, but did not change the phenotypic profile. 
SZ-2 (GP Ib)
AN-51 (QP Ib)
LOG RED FLUORESCENCE Fig 7 . Surface antigen analysis of MP in the supernate of a control PC as shown with primary antibodies followed by a PE-labeled second antibody (red fluorescence). After antibody addition, DiOC, was added (green fluorescence) t o mark membranous material. The top two panels show a polyclonal antiserum raised in rabbits against human platelets (right column) versus background fluorescence with goat antirabbit second antibody alone (left column). The other panels show MoAb binding versus background with a non-immune primary mouse IgG2a followed by the goat antimouse second antibody (left column, second row). The primary MoAbs used were: 10E5 against platelet GPllbllla, SZ-2 and AN-51 against platelet GPlb, HLE against human leukocytes, and D2-10 against human erythrocyte glycophorin. The bright red material appearing in each of the lower six panels was later found t o be aggregated second antibody.
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From cells or particles. In addition, data from measurements of scattered light can yield information on particle size and apparent granularity. The light scatter distribution of platelets is quite broad, reflecting the great heterogeneity of platelet size (2 to 20 fL) and density (1.08 to 1.04 g/cm3), and it has been reported that the distribution broadens during storage of platelet concentrates." Thus, it is difficult to identify clearly where the distribution of intact platelets ends and smaller particles, such as released membranous vesicles, begins. On the assumption that vesiculation of platelets results in particles of various size, but decidedly lower density than the intact cell, we elected to use centrifugation to sediment intact platelets before analysis of remaining MP. However, this approach has the disadvantage of possible loss of MP through co-sedimentation with the intact platelets, leading to underestimation of MP concentration. Our findings were lower than might be expected in that the MP counts were less than 10s/mL on average in PC containing greater than lo9 platelets/mL. A light centrifugation (7,500g-minute) resulted in more supernatant MP than the usual protocol (30,000g-minute), but there may have also been more platelets remaining as indicated by the Coulter Counter. The distribution of particles greater than 0.5-pm diameter may have included platelet-sized material, or even a few less dense intact platelets, in both types of preparations. We assume that the majority of light scattering events analyzed in these experiments represented vesicles of platelet membrane or the vacuolated ghost left after vesiculation, such as those forms observed by Sims et aI.'zs We assume also that there are many that were not observable within our analytical window.
Transmission electron micrographs of MP released during collagen stimulation of human platelets have demonstrated in other studies at least two different populations: one with an apparent diameter of 0.4 to 0.6 pm, and the other in the size range of 0.08 to 0.2 pm., With the light scatter settings used in this study, the flow cytometer could detect unlabeled latex spheres with a nominal diameter of 0.26 pm (data not shown) before encountering significant electronic noise. Further reduction in thresholds or increase in amplifier gain settings caused an immediate overflow of count accumulation that we interpreted as "background" light scatter in the plasma, or in the fluidics of the cytometer, probably originating from lipoprotein structures, macromolecular complexes, or even microbes. With these restrictions, the smaller population of MP (0.08 to 0.2 pm) possibly present in the PC was most likely lost in the background. Our attempts to analyze MP in highly diluted samples at the most sensitive light scatter thresholds produced event counts of 109/mL or higher, but 60% to 80% of the particles were negative for DiOC, uptake and less than 10% were positive for the monoclonal platelet markers. Interestingly, the polyclonal antiserum marked as much as 50% of the material, but the specificity of this finding remains open to question.
Despite these limitations, our data show a significant effect of platelet activation inhibitors and reduced S/V ratio on MP generation in PC stored for transfusion. The predominant population of MP analyzed was larger than 0.5 pm in apparent diameter by forward angle light scatter, and it was this population that was most affected by the inhibitors. Also, this larger population of MP was highly correlated with levels of PF3 activity in the supernatant plasma and showed the most positivity with the antibody probes to human platelet surface antigens. The population of smaller MP (less than 0.5-pm diameter) did not correlate statistically with PF3 activity and was not reduced in the inhibitor-treated PC. This population comprised approximately 16% of the total MP count in control PC and 29% in the inhibitor-treated concentrates, reflecting the specific effect of the inhibitors on generation of larger MP during storage. In stored PPP bags, the smaller MP comprised approximately 35% of the total MP count with no demonstrable shift due to inhibitors. Both large and small MP took up DiOC,, but the few negative MP observed at our standard settings were small (in quadrant 111).
Staining with MoAbs and a polyclonal antiserum demonstrated that the majority of the observed MP were of platelet origin instead of fragments of erythrocytes or leukocytes. The DiOC, hydrophobic dye showed that the particles under study were membranous, rather than aggregates of platelet GP or lipoproteins in the surrounding plasma. Expression of PF3 activity by the MP also indicated the presence of a membrane surface. The relatively greater percentage of positivity seen with the 10E5 antibody to GPIIbIIIa versus the SZ-2 or AN-51 antibody to GPIb suggests a different distribution of surface GP on MP relative to fresh platelets. Previous studies have demonstrated the appearance of a surface GPIb-negative population of platelets during tora age'^.^^ although others have shown that optimizing the agitation method results in no demonstrable loss of GPIb during storage for 5 days." Platelet activation by thrombin has been shown to alter the binding of markers of GPIb.21*22 We have shown elsewhere" that inhibitors of platelet activation retard the loss of platelet GPIb in extended storage of PC. Perhaps vesiculation of platelets during storage contributes to the loss of surface GPIb, but lack of GPIb on the majority of MP suggests that proteolysis or internalizationu of GPIb may occur during or after vesiculation.
The release of LDH from platelets and the appearance of supernatant PF3 activity were both correlated with MP count in the PC. It has been known for quite some time that activation of platelets by chemical stimulation results in PF3 expression, but generally very little LDH is released in the short-term incubations usually However, extended incubation over several days, as in our storage experiments, with the many potential agonists present,= may provide the opportunity for a slow leakage of LDH to accumulate to significant levels. We did not observe a large or consistent decrease in platelet count in the concentrates during storage ( < 10% decrease), indicating that complete cell lysis was not the cause of high levels of extracellular For personal use only. on March 31, 2017. by guest www.bloodjournal.org From LDH seen in the controls versus the inhibitor-treated units. We suggest instead that the active process of vesiculation of platelets in vitro results in the generation of membranous MP and a platelet "ghost" with compromised membrane integrity. This hypothesis would appear to be consistent with the morphologic observations of Sims et al7.* in regards to activation of platelets by sublytic activity of complement. Although we have not found direct evidence of terminal complement activation in stored PC,26 the inner wall of the plastic container may provide a site for occult complement fixation that could interact with platelets during storage. The observed benefit of a reduced bag S/V ratio may be at least partially related to a reduction in platelet collision rate with active complement components on the bag wall. Our finding that a cocktail of platelet activation inhibitors greatly enhanced the reduction in MP count (and PF3 activity and LDH release) is consistent with this hypothesis, but may indicate that also soluble-phase activation of platelets contributes to vesiculation during storage. The specific role of aprotinin in the cocktail of inhibitors has yet to be determined, but it does appear to augment the other component^.'^ We conclude that platelets vesiculate during storage for transfusion largely by an activation-dependent process. It has long been known that stored erythrocytes release membranous vesicles into the supernatant fluid as their adenosine triphosphate (ATP) reserves are depleted." Perhaps the depletion of ATP in platelets after a metabolic burst associated with activationz8 leads to platelet vesiculation in much the same manner. Directly or indirectly, the presence of MP provides more evidence that platelet activation occurs during the storage of PC and may contribute to the resulting platelet storage l e s i~n .~~~*~ It is now apparent that inhibition of MP generation is part of the previously noted beneficial effects of platelet activation inhibitors on storage of platelet^.'^?'^
